Is Botanix Pharmaceuticals Limited (BXPHF) a Buy, Sell, or Hold?
OTC : BXPHF
Botanix Pharmaceuticals Limited
$0.013 USD
$0 (0.0%)
- Volume
- 125K
- Average Volume
- 18.11K
- Market Capitalization
- $25.9M
- P/E Ratio
- -0.49
- Dividend Yield
- 0.00%
- Price Target
- $0.27
- Year High
- $0.14
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.56
Company Overview
OTC
Howie McKibbon
Medical - Pharmaceuticals
Healthcare
BXPHF
11
AU
USD
Liquidity Metrics
0.57
2.56
1.56
1.14
0.00
Sales & Valuation
$5.76M
2.09
0.84
-0.57
-0.04
Profitability
-$0.0468
-$86.4M
-404.72%
-404.72%
-131.13%
-89.99%
P/E Metrics
-0.49
0.00
0.00
Analyst Price Target & Rating
$0.27
$0.27
$0.27
1/5
0 Analysts
-95.19%
Financial Health Scores
-5.91
3/9
$43.06M
$98.53M
$44.56M
-$124.99M
Key Metrics (TTM)
$44.88M
2.05
-0.55
2.56
-131.13%
-99.26%
-196.35%
-176.45%
252 days
Company Executives
| Name | Title |
|---|---|
| Boris Meyerson | Chief Business Officer |
| Howie McKibbon | Chief Executive Officer |
| Chris Lesovitz | Chief Financial Officer of United States of America |
| Darin Van Arsdale | Director of Sales Operations |
| Andrew Bickley | Joint Company Secretary |
| Paul Seaback | Chief Operating Officer |
| Vincent Ippolito | MD & Executive Chairman |
| Kevin Wojciechowski | Head of HCP Marketing & Sales Training |
| David Morgan | Head of Corporate Affairs |
| Graeme Morissey | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Botanix Pharmaceuticals Limited (OTC:BXPHF) Stock
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in West Perth, Australia. ...
2026-04-29 00:31:47
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Sofdra Update Transcript
Frequently Asked Questions
-
What is the current Botanix Pharmaceuticals Limited (BXPHF) stock price?
-
Botanix Pharmaceuticals Limited(OTC:BXPHF) stock price is $0.013 in the last trading session. During the trading session, BXPHF stock reached the peak price of $0.1413 while $0.0114 was the lowest point it dropped to. The percentage change in BXPHF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BXPHF stock was $0.
-
BXPHF's industry and sector of operation?
-
The OTC listed BXPHF is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of BXPHF?
-
Boris Meyerson | Chief Business Officer
Howie McKibbon | Chief Executive Officer
Chris Lesovitz | Chief Financial Officer of United States of America
Darin Van Arsdale | Director of Sales Operations
Andrew Bickley | Joint Company Secretary -
How many employees does BXPHF have?
-
Number of BXPHF employees currently stands at 11. BXPHF operates from 41-47 Colin Street, West Perth, WA 6005, AU.
-
Link for BXPHF official website?
-
Official Website of BXPHF is: https://www.botanixpharma.com
-
How do I contact BXPHF?
-
BXPHF could be contacted at phone #61 8 6555 2945 and can also be accessed through its website. BXPHF operates from 41-47 Colin Street, West Perth, WA 6005, AU.
-
How many shares of BXPHF are traded daily?
-
The average number of BXPHF shares traded daily for last 3 months was 18.11K.
-
What is the market cap of BXPHF currently?
-
The market value of BXPHF currently stands at $25.9M with its latest stock price at $0.013